Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES
10 MARCH 2025 at 19.00 EET           

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2025 transferred altogether 191,911 Orion Corporation B shares held by the company as a share reward for earning period 2022–2024 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022.

The price per share of the transferred shares is EUR 53.7158, which is the volume weighted average quotation of the Orion Corporation B share on 10 March 2025. Accordingly, the total transaction price of the transferred shares is EUR 10,308,652.89.

After the share transfer, the total number of own B shares held by Orion Corporation is 440,944.

Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 10 February 2022.


Orion Corporation

Liisa Hurme
President and CEO
    Olli Huotari
EVP, Corporate Functions
 

                                                 
Contact person:
Olli Huotari, EVP, Corporate Functions
tel. +358 10 426 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service